Jatenzo Legal and Patent Challenges

FDA Approval History and the Road to NDA 206089

Jatenzo became the first oral testosterone capsule approved in the U.S. on March 27, 2019, under NDA 206089. The approval followed decades of failed attempts by multiple companies to develop an oral testosterone that could survive first-pass hepatic metabolism without causing liver toxicity.

The drug uses a self-emulsifying formulation of testosterone undecanoate dissolved in lipid excipients. This design routes absorption through the intestinal lymphatic system rather than the portal vein, which reduces hepatic exposure. Earlier oral androgens like methyltestosterone and fluoxymesterone carried hepatotoxicity risks (including peliosis hepatis and cholestatic jaundice) that made regulators wary of any oral testosterone product [1].

Clarus Therapeutics, the original developer, submitted its first NDA in 2014. The FDA issued a complete response letter (CRL) citing concerns about blood pressure elevations observed during clinical trials. A second CRL followed in 2015. Only after a reformulated product and additional cardiovascular monitoring data did the agency grant approval in 2019, with a requirement for post-marketing studies [2]. That extended review timeline, spanning five years and two rejections, foreshadowed the regulatory scrutiny that would continue after launch.

The Key Trial: Swerdloff et al. (2020)

The registration study enrolled 166 hypogonadal men and demonstrated that Jatenzo could restore serum testosterone to the eugonadal range (300 to 1,100 ng/dL) in approximately 87% of subjects at the final titrated dose. Swerdloff and colleagues published the results in the Journal of Clinical Endocrinology & Metabolism, reporting a mean steady-state C_avg of 489 ng/dL across the dose-titration cohort [3].

The trial used a dose-titration protocol starting at 237 mg twice daily, with adjustments to 158 mg or 316 mg twice daily based on serum testosterone levels measured at specified intervals. This is not a fixed-dose product. Clinicians must check levels at approximately one month and adjust accordingly, a requirement that adds clinical burden compared to injectable testosterone cypionate, which most providers already dose by established protocols.

Blood pressure increases of 3 to 5 mmHg systolic were observed in the Jatenzo arm relative to baseline. The FDA flagged this finding during the original NDA review, and it contributed to both CRLs. While the magnitude may seem modest, the agency's cardiovascular advisory committee noted that even small population-level BP shifts translate into measurable increases in stroke and myocardial infarction rates over years of chronic use [4].

Cardiovascular Black Box Warning (2023)

In January 2023, the FDA mandated a class-wide labeling change for all testosterone products, including Jatenzo. The updated label carries a black box warning about major adverse cardiovascular events (MACE), specifically myocardial infarction and stroke [5].

This decision drew on data from the TRAVERSE trial (N=5,246), which randomized hypogonadal men aged 45 to 80 with cardiovascular risk factors to transdermal testosterone gel versus placebo. The primary MACE endpoint showed a hazard ratio of 0.96 (95% CI: 0.78 to 1.17), meaning testosterone did not increase MACE in that particular population. But the FDA opted for a precautionary class-wide warning regardless, citing the blood pressure signal in the Jatenzo data and the inability to rule out harm in subgroups not represented in TRAVERSE [6].

For Jatenzo specifically, the warning carries outsized commercial weight. The product already faced prescriber hesitancy because of its higher cost relative to generic injectable testosterone cypionate (which runs approximately $30 to $60 per month at many pharmacies). Adding a black box warning to a product that costs over $500 per month without insurance creates a compounding barrier to adoption.

The Endocrine Society's 2018 clinical practice guideline states: "We recommend testosterone therapy for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" (Bhasin et al., 2018) [7]. That guideline, written before the class-wide warning, did not differentiate among formulations on a cardiovascular safety basis. Whether the Society updates its position to address oral-specific hemodynamic data remains an open question.

Patent Disputes and Paragraph IV Challenges

Clarus Therapeutics listed several patents in the FDA's Orange Book covering Jatenzo's lipid-based self-emulsifying formulation and its dose-titration method. These patents include U.S. Patent Nos. 9,480,690, 9,757,390, and 10,loosely related continuation patents extending protection into 2029 and beyond [8].

Generic drug makers have filed Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications, asserting that one or more of these patents are invalid or would not be infringed by their proposed generic formulations. Under the Hatch-Waxman Act, each Paragraph IV filing triggers a 45-day window for the brand company to file suit, which activates a 30-month stay of FDA approval for the generic.

Clarus Therapeutics filed for Chapter 11 bankruptcy protection in 2022, complicating the enforcement of these patents. Tolmar Pharmaceuticals subsequently acquired the Jatenzo asset. The transfer of patent rights during bankruptcy proceedings introduced legal ambiguity about standing to enforce certain Orange Book-listed patents, which generic challengers have attempted to exploit in litigation [9].

The core legal question in pending Paragraph IV cases centers on formulation claims. Generic applicants argue that the lipid excipient blend used in Jatenzo's capsule is not novel enough to warrant patent protection, pointing to prior art from European testosterone undecanoate products (Andriol, marketed by Organon outside the U.S. for decades) that used similar lipid-based delivery systems. Tolmar counters that the specific self-emulsifying drug delivery system (SEDDS) composition and its pharmacokinetic profile are distinct from Andriol's older formulation [10].

Label Restrictions and the "Known Etiology" Requirement

The Jatenzo label restricts the approved indication to men with "conditions that cause hypogonadism due to known medical conditions." The FDA explicitly excludes age-related testosterone decline (sometimes called "late-onset hypogonadism") from the approved indication.

This restriction mirrors the class-wide testosterone labeling change the FDA implemented in 2015, which required all testosterone products to specify that they are approved only for men with low testosterone caused by disorders of the testes, pituitary, or hypothalamus [5]. The practical effect is significant: a large proportion of testosterone prescriptions in the U.S. are written for men whose primary finding is a low serum testosterone level without a clearly documented structural or genetic etiology.

For Jatenzo, this label restriction compounds commercial challenges. Prescribers treating age-related hypogonadism with off-label testosterone are unlikely to choose a more expensive oral formulation when cheaper injectables are available and carry the same regulatory ambiguity regarding indication. The "known etiology" language also creates medicolegal exposure for clinicians if adverse events occur in patients prescribed Jatenzo outside the labeled population.

The label also includes specific instructions about food requirements. Jatenzo must be taken with food, and fatty meals increase absorption. This is not a minor footnote. In the key trial, fasting administration reduced the area under the curve by roughly 40%, meaning patients who skip meals or take the capsule on an empty stomach may not achieve therapeutic testosterone levels [3].

Post-Marketing Surveillance Requirements

As a condition of approval, the FDA required Clarus (now Tolmar) to conduct post-marketing studies evaluating the long-term cardiovascular safety of Jatenzo. These requirements fall under Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act, which grants the agency authority to mandate post-approval studies when safety signals warrant ongoing evaluation [11].

The required studies include long-term blood pressure monitoring in hypogonadal men treated with Jatenzo versus injectable testosterone, as well as evaluation of hepatic safety markers over extended dosing periods. Despite the lymphatic absorption pathway, the FDA wanted confirmation that chronic oral testosterone undecanoate exposure does not produce delayed hepatotoxicity, given the historical association between oral androgens and liver injury [2].

Tolmar has not publicly disclosed interim results from these post-marketing commitments. The FDA's post-marketing requirement (PMR) tracker shows the studies as "pending," a status that has persisted for several years. Delayed or incomplete PMR fulfillment could expose the company to enforcement action, including potential label modifications or marketing restrictions.

Competitive and Legal Pressures from Other Oral Testosterone Products

Jatenzo does not exist in isolation. Tlando (oral testosterone undecanoate) received FDA approval in 2022 from Halozyme Therapeutics, using a similar lipid-based formulation but a different dosing regimen. The entry of a second oral testosterone product adds competitive pressure and complicates Jatenzo's patent position, because the existence of Tlando demonstrates that the broad concept of oral testosterone undecanoate in a lipid carrier does not belong exclusively to Jatenzo's IP estate [12].

Kyzatrex, another oral testosterone undecanoate product, also gained approval, further crowding the oral TRT segment. Each new entrant increases the likelihood that courts will construe Jatenzo's formulation patents narrowly, limiting them to the specific excipient ratios and SEDDS composition rather than the general principle of lymphatic absorption of testosterone undecanoate.

The Endocrine Society has not issued specific guidance differentiating among the three approved oral testosterone undecanoate products. From a clinical pharmacology standpoint, all three rely on the same active pharmaceutical ingredient and the same lymphatic absorption mechanism. The differentiation lies in excipient composition, capsule design, and dosing titration protocols. Whether those differences are sufficient to sustain patent protection is the central question in ongoing litigation.

What Clinicians Should Know Now

Prescribers considering Jatenzo for hypogonadal patients should verify the diagnosis meets the "known etiology" requirement on the current label. Blood pressure should be monitored at baseline and within the first month of therapy. Dose titration requires a follow-up testosterone level at approximately four weeks, with adjustment to the 158 mg or 316 mg twice-daily dose based on the measured C_avg.

The mean wholesale acquisition cost of Jatenzo exceeds $6,000 per year without insurance, versus approximately $360 to $720 annually for generic testosterone cypionate 200 mg/mL (GoodRx pricing data). Cost conversations are clinically relevant and should be documented. Patients should be counseled to take the capsule with a meal containing at least 15 grams of fat to ensure adequate absorption [3].